Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Terminated 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Sarcoma 1Other hematologic neoplasm 1Myeloid 1

Conditions

Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Primary Myelofibrosis 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × INCB059872 × Clear all
NCT02712905 2025-11-04

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
116 enrolled 36 charts
MyeloidOther hematologic neoplasmThoracic

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Primary Myelofibrosis, Small Cell Lung Carcinoma

NCT02959437 2025-10-21

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

Incyte Corporation

Phase 1/2 Terminated
70 enrolled 14 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT03514407 2025-10-21

A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma

Incyte Corporation

Phase 1 Terminated
25 enrolled
Sarcoma

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡